CEFYBO   02669
CENTRO DE ESTUDIOS FARMACOLOGICOS Y BOTANICOS
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
Potential immunomodulatory effect of human chorionic gonadotrophin in patients with multiple sclerosis
Autor/es:
JURIOL LORENA VANESA; QUIROGA, MARÍA FLORENCIA ; VALEFF, NATALÍN; CORREALE, JORGE; VENTIMIGLIA, MARÍA SILVIA; JENSEN, FEDERICO
Lugar:
Buenos Aires
Reunión:
Congreso; Reunión Conjunta de Sociedades de Biociencias; 2017
Institución organizadora:
Sociedad Argentina de Inmunología (SAI)
Resumen:
Multiple sclerosis (MS) is an invalidating, neurodegenerative disease, 2-3 times more common in women than men. It is well known that pregnancy has a strong influence on MS disease activity and, a reduced relapse frequency (70%) is seen during pregnancy. Human chorionic gonadotropin (hCG) is synthetized by the placenta during pregnancy and the presence of its receptor has been described in immune cells, such as B and T cells. The aim of our study was to investigate the capability of hCG to reduce activation and later production of pro-inflammatory cytokines from immune cells in MS patients. We recruited women suffering MS during their reproductive life. PBMC were isolated from whole blood samples and then cultivated in vitro with/without (control, C) hCG: urinary hCG (u, 100 IU/ml) or recombinant hCG (r, 5 ug/ml) for 24 h. PMA, Ionomycin and Brefeldin A were added, in some wells, for the last 5h of culture. Flow cytometry was used for the phenotypical characterization of different immune cell subsets: CD19, CD80, CD86 (B cells), CD4 and Foxp3 cells and to evaluate intracellular cytokines levels: TNF-α and IL-10. We observed that treatment with hCGu significantly reduced the relative numbers of CD19+CD86+ B cells as compared to control group. No changes were observed concerning CD80+ expressing B-lymphocytes. Interestingly, addition of either hCGu or hCGr induced a significant reduction in the total numbers of CD19+TNF-α+ B cells as well as CD4+TNF-α+ cells as compared to controls. Besides a slight increase, no significant differences were observed on IL-10 production by CD4+ or CD19+ B cells upon either hCG stimulation (data were analyzed by One-way ANOVA). Overall, we demonstrated here that treatment with hCG in vitro, lowers the expression of the costimulatory molecule CD86 in B cells and also decreases the production of TNF-α, in both CD4+ and CD19+ B cells. These results highlight the potential use of this hormone for the treatment of MS.